1 |
任成山,王关嵩,钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
|
2 |
Klaus FR, Henrik W. Chronic obstructive pulmonary disease[J]. Lancet, 2017, 389(10082): 1931-1940.
|
3 |
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-20128.
|
4 |
Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy,years of life lost, and all-cause and cause specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories[J]. Lancet, 2018, 392 (10159): 2052-2090.
|
5 |
Inmaculada A, Pilar de L, Julio A, et al. 10 Years after EPISCAN: A New Study on the Prevalence of COPD in Spain-a Summary of the EPISCAN Ⅱ Protocol[J]. Arch Bronconeumol, 2019, 55(1): 38-47.
|
6 |
Miravitlles M, Soler-cataluna JJ, Calle M, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease GESEPOC 2017.Pharmacological Treatment of Stable Phase[J]. Arch Bronconeumol, 2017, 53 (6): 324-335.
|
7 |
Pleguezuelos E, Gimeno SE, Hernandez C, et al. Recommendations on non-pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GESEPOC 2017)[J]. Arch Bronconeumol, 2018, 54 (11): 568-575.
|
8 |
Sietske van der L, Marieke LD. High-intensity non-invasive ventilation in stable hypercapnic COPD: evidence of efficacy and practical advice[J]. Respirology, 2019, 24(4): 318-328.
|
9 |
Ram FSM, Picot J, Lightowler J, et al. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2004, (1): CD004104.
|
10 |
Vasiliki T, Chaido P, Eleni K, et al. One-year non-invasive ventilation in chronic hypercapnic COPD: Effect on quality of life[J]. Respir Med, 2008, 102(6): 904-911.
|
11 |
元 梅,韩其政,赵 慧,等. 家庭无创正压通气对COPD合并呼吸衰竭病人生活质量的影响[J]. 中国老年学杂志,2012, 32(20): 4561-4563.
|
12 |
Holland AE, Spruit MA, Troosters T, et al. An Offificial European Respiratory Society/American Thoracic Society Technical Standard: fifield walking tests in chronic respiratory disease[J]. Eur Respir J, 2014, 44(6): 1428-1246.
|
13 |
Hernandes NA, Wouters EF, Meijer K, et al. Reproducibility of 6-minute walking test in patients with COPD[J]. Eur Respir J, 2011, 38(2): 261-267.
|
14 |
孙 雅,张彩莲. 长期家庭无创通气对慢性阻塞性肺疾病应用进展的探析[J]. 世界最新医学信息文摘,2018, 18(68): 75-76, 84.
|
15 |
Barnes PJ. Mediators of chronic obstructive pulmonary disease[J]. Pharm Rev, 2004, 56(4): 515-548.
|
16 |
Shahriary A, Ghanei M, Rahmani H. The systemic nature of mustard lung: comparison with COPD patients[J]. Interdiscip Toxicol, 2017, 10(3): 114-127.
|
17 |
Castellucci M, Rossato M, Calzetti F, et al. IL-10 disrupts the Brd4- docking sites to inhibit LPS-induced CXCL8 and TNF-α expression in monocytes: implications for chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2015, 136(3): 781-791.
|
18 |
Al-shair Khaled, Umme K, Rachel D, et al. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD[J]. Respir Res, 2011, 12(1): 3.
|
19 |
朱幼鸣,胡 辉,曾 烨. 无创正压通气辅助治疗对COPD合并Ⅱ型呼吸衰竭患者血气参数、心功能及炎症状态的影响[J]. 海南医学院学报,2017, 23(3): 327-330.
|
20 |
王新杰. 孟鲁司特钠联合BiPAP呼吸机对COPD合并呼吸衰竭患者CRP、TNF-α、NT-proBNP的影响[J]. 标记免疫分析与临床,2016, 23(9): 1024-1026.
|
21 |
袁一帆,莫伟良,袁楚樊. 无创正压通气治疗对COPD合并Ⅱ型呼吸衰竭患者血气参数及炎症状态的影响[J]. 白求恩医学杂志,2019, 17(2): 147-149.
|
22 |
杨东霞,苏炜欣,黄晓霞. 无创正压通气+常规治疗在COPD并Ⅱ型呼吸衰竭患者中的应用价值[J]. 中国医学创新,2019, 16(16): 68-71.
|
23 |
周松林,徐文波. 无创机械通气治疗慢性肺源性心脏病合并Ⅱ型呼吸衰竭的临床疗效[J]. 中国现代医学杂志,2015, 25(12): 106-109.
|
24 |
王春芳,于耀龙,赵富栋. 孟鲁司特钠联合双水平气道正压通气呼吸机治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果[J]. 中国临床实用医学,2018, 9(4): 25-29.
|
25 |
赵树凯. 孟鲁司特钠对COPD急性加重期患者肺功能和诱导痰TNF-α、IL-8的影响[J]. 北方药学,2019, 16(5): 76-77.
|